Olmetec (Olmesartan Medoxomil)

Olmesartan medoxomil is a pro‑drug that is converted in the body to olmesartan, which selectively blocks AT‑1 receptors for angiotensin II. By preventing angiotensin II from binding, the drug stops vasoconstriction and aldosterone release, leading to relaxed blood vessels and lower systemic blood pressure.

The dose of Olmetec is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, kidney function and other medical factors. The prescriber determines the appropriate strength and titration schedule according to current clinical guidelines.

Olmesartan medoxomil is contraindicated in the second and third trimesters of pregnancy because it can cause fetal toxicity. Safety during breastfeeding has not been established, so it should be used only if the potential benefit justifies the possible risk to the infant.

To place an order, submit an enquiry on the Olmetec product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmetec belongs to the ARB class, which offers blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle, providing an alternative mechanism for patients who need combination therapy.

Olmetec tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Keep the container tightly closed, protect from moisture and light, and discard any tablets that appear discoloured or damaged.

Olmetec is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the timing without medical advice.

Serious adverse events linked to Olmetec include angio‑edema, severe hypotension, acute kidney injury, hyper‑kalemia and rare skin reactions such as bullous pemphigoid. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or unexplained changes in kidney function.

Olmetec should not be used by individuals with known hypersensitivity to olmesartan or any component of the formulation, pregnant women in their second or third trimester, and patients with severe hepatic impairment unless specifically directed by a physician. Caution is also advised for those with significant renal dysfunction.